David Crosiers

List of Publications by Year in Descending Order

34 papers	1,315 citations	17 h-index	36 g-index
39 ext. papers	1,557 ext. citations	5.3 avg, IF	3.46 L-index

#	Paper	IF	Citations
34	Impaired bed mobility in prediagnostic and de novo Parkinson's disease.. *Parkinsonism and Related Disorders*, **2022**, 98, 47-52	3.6	
33	Cerebellar ataxia in progressive supranuclear palsy: a clinico-pathological case report. *Acta Neurologica Belgica*, **2021**, 121, 599-602	1.5	
32	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. *Acta Neuropathologica Communications*, **2021**, 9, 25	7.3	7
31	REM sleep without atonia and nocturnal body position in prediagnostic Parkinson's disease. *Sleep Medicine*, **2021**, 84, 308-316	4.6	1
30	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. *Acta Neuropathologica*, **2020**, 139, 1001-1024	14.3	27
29	Myoclonus and cerebellar ataxia following Coronavirus Disease 2019 (COVID-19). *Movement Disorders Clinical Practice*, **2020**, 7, 974	2.2	30
28	Polysomnographic phenotype of isolated REM sleep without atonia. *Clinical Neurophysiology*, **2020**, 131, 2508-2515	4.3	5
27	Impulsive-Compulsive Behaviours in Belgian-Flemish Parkinson's Disease Patients: A Questionnaire-Based Study. *Parkinson's Disease*, **2019**, 2019, 7832487	2.6	1
26	Spectrum of Movement Disorders in 18p Deletion Syndrome. *Movement Disorders Clinical Practice*, **2019**, 6, 70-73	2.2	4
25	Frequency and characteristic features of REM sleep without atonia. *Clinical Neurophysiology*, **2019**, 130, 1825-1832	4.3	6
24	REM sleep without atonia and the relation with Lewy body disease. *Parkinsonism and Related Disorders*, **2019**, 67, 90-98	3.6	11
23	Reply to: The Spectrum of Movement Disorders in 18p Deletion Syndrome. *Movement Disorders Clinical Practice*, **2019**, 6, 731-732	2.2	
22	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. *Neurobiology of Aging*, **2017**, 49, 217.e1-217.e4	5.6	5
21	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. *Neuroscience Letters*, **2016**, 629, 160-164	3.3	19
20	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. *Neurology*, **2015**, 85, 1283-92	6.5	20
19	Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment. *Journal of Neurology*, **2015**, 262, 7-20	5.5	15
18	Mindfulness Training among Individuals with Parkinson's Disease: Neurobehavioral Effects. *Parkinson's Disease*, **2015**, 2015, 816404	2.6	49

17	Alpha-synuclein repeat variants and survival in Parkinson's disease. *Movement Disorders*, **2014**, 29, 1053-7	7	11
16	Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. *Neurology*, **2014**, 83, 1906-13	6.5	49
15	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. *JAMA Neurology*, **2013**, 70, 727-35	17.2	285
14	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. *Journal of Medical Genetics*, **2012**, 49, 721-6	5.8	78
13	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. *Neurobiology of Aging*, **2012**, 33, 629.e5-629.e18	5.6	52
12	Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population. *Neurobiology of Aging*, **2012**, 33, 1844.e11-3	5.6	18
11	Large-scale replication and heterogeneity in Parkinson disease genetic loci. *Neurology*, **2012**, 79, 659-67	6.5	106
10	Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa-responsive dystonia. *Movement Disorders*, **2012**, 27, 1451-6	7	9
9	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. *American Journal of Neurodegenerative Disease*, **2012**, 1, 160-7	2.5	21
8	Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. *Journal of Chemical Neuroanatomy*, **2011**, 42, 131-41	3.2	51
7	Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. *Parkinsonism and Related Disorders*, **2011**, 17, 135-8	3.6	48
6	GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. *Neurobiology of Aging*, **2011**, 32, 308-12	5.6	8
5	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. *Neurobiology of Aging*, **2011**, 32, 548.e9-18	5.6	46
4	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. *Lancet Neurology, The*, **2011**, 10, 898-908	24.1	237
3	Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2010**, 153B, 220-8	3.5	10
2	Comprehensive genetic and mutation analysis of familial dementia with Lewy bodies linked to 2q35-q36. *Journal of Alzheimer's Disease*, **2010**, 20, 197-205	4.3	17
1	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. *Human Mutation*, **2009**, 30, 1054-61	4.7	52